


<b>Price</b>	<b>113.5p</b>
Market Cap	£327.6m
Shares in issue	289m
12m Trading Range	86p – 154p
Free float	73%
Next Event	Q2 results – 30 August

Price performance (p)



Source: Bloomberg

Financial forecasts

Yr end Dec (\$'m)	2021A	2022E	2023E	2024E
Revenue	410.5	617.1	654.1	693.4
YoY growth (%)	71.0	50.3	6.0	6.0
Gross profit	118.5	170.8	180.5	190.9
Adj. EBITDA	46.3	70.0	75.7	79.7
YoY growth (%)	57.3	51.3	8.1	5.3
EBITDA margin (%)	11.3	11.3	11.6	11.5
EBITDA margin (Net revenue) (%)	39.0	41.0	41.9	41.8
EPS (c) basic adj.	11.8	17.4	18.8	20.2
DPS (p)	-	-	0.8	1.8
Net cash (debt)*	(81.4)	(51.2)	(11.5)	34.6
EV/EBITDA (x)	8.3	6.0	5.2	4.4
EV/EBIT (x)	9.0	6.4	5.5	4.6
P/E (x)	11.6	7.8	7.2	6.7
FCFF yield (%)	9.1	12.5	13.2	17.4

\* Includes FX hedging liabilities  
Source: Audited Accounts and Zeus estimates

\* CentralNic is a NOMAD and Broking client of Zeus

Analyst

Bob Liao, CFA +44 20 3829 5614  
[bob.liao@zeuscapital.co.uk](mailto:bob.liao@zeuscapital.co.uk)

Zeus Contacts

Emma Ayton	+44 20 3829 5622
Victoria Ayton	+44 20 3829 5603
Mike Cuthbert	+44 131 370 3704
Dominic King	+44 20 3829 5607
Gregor Paterson	+44 131 370 3705
Ben Robertson	+44 20 3829 5625
Nick Searle	+44 20 3829 5633
Rupert Woollfenden	+44 20 3829 5623

Email [firstname.surname@zeuscapital.co.uk](mailto:firstname.surname@zeuscapital.co.uk)

# CentralNic

CNIC LN - Technology

## Accelerating growth and upgraded outlook

CentralNic's LTM pro forma revenue growth accelerated again to 62% in Q2 2022, resulting in revenue of \$335m and Adjusted EBITDA of \$38m in H1. The company upgraded guidance, which appears very conservative. Even in the unlikely case of a sharp downturn leading to 16% sequential decline in Adjusted EBITDA in H2, the company would still meet revised guidance. We raise our 2022 revenue forecast by 8% to \$617m and our Adjusted EBITDA by 4% to \$70m and see the potential for strong earnings outperformance. Even based on our conservative forecasts, shares appear attractively valued at 6x 2022 EBITDA, 8x P/E and 12.5% FCFF yield. With increased estimates our valuation for CentralNic is lifted to 221p from 195p.

### H1 trading update

- Long track record of accelerating growth:** LTM pro forma revenue growth was an impressive 62% in Q2 and extends CentralNic's long track record of accelerating growth from 53% in Q1, 37% in 2021 and 20% in 2020. There appears to be no signs of the potential weakness in CentralNic's Online Marketing market that may be factored into the share price.
- Strong profits and cash generation:** Adjusted EBITDA is expected to be \$38m, resulting in margin of c.11.3% and in line with margins in 2021. Net debt including foreign exchange hedge liabilities is expected to be \$65m, which is down by only \$5.7m from \$70.7m at the end of Q1. The relatively small decline in net debt is due to a sizable increase in hedging liabilities to \$16.6m from \$9.4m at the end of Q1. Excluding FX hedging liabilities, net debt would have fallen by \$12.9m, which is c.66% of Q2 Adjusted EBITDA (c.\$19.5m). The company estimated that adjusted operating cash conversion was over 100% in H1 2022.
- Guidance factors in extraordinary downturn:** Given the strong H1 results, the company is now confident that full year 2022 results will be at least at the high end of the current market expectations (\$603m revenue and \$70m Adjusted EBITDA). This revised guidance factors in an extraordinary downturn in H2 2022, equivalent to sequential revenue decline of 20% and Adjusted EBITDA decline of 16%.
- Conservative forecast upgrade:** We conservatively forecast \$617m of revenue in 2022, 2% above the top end of current consensus, and Adjusted EBITDA of \$70m, in line with the top end of current consensus. We estimate 37% pro forma growth in 2022, well below 62% pro forma growth already achieved in H1. (See charts overleaf for details.)
- Value for growth:** Based on our conservative estimates, shares trade at only 6x 2022 EBITDA, 8x P/E and 12.5% FCFF yield. We raise of our DCF valuation from 195p to 221p, which is about 2x the current share price. Note that CentralNic shares were included in the AIM 100 and AIM UK 50 indices on 20 June 2022.

Disclaimer: This research is intended for institutional investors only. It is intended for, and should not be relied upon, by retail customers and any retail customer should seek professional, independent advice before investing. For FCA purposes this marketing communication has not been prepared in accordance with legal requirements to promote the independence of investment research. Zeus is not subject to any prohibition on dealing ahead of the dissemination of such investment research


## Forecast revisions

Exhibit 1: Forecast revisions

Year to Dec (\$m)	2022E (new)	2022E (old)	% diff	2023E (new)	2023E (old)	% diff	2024E (new)	2024E (new)	% diff
Revenue	617.1	573.4	7.6	654.1	607.3	7.7	693.4	643.4	7.8
Adj EBITDA	70.0	67.0	4.5	75.7	72.3	4.6	79.7	76.1	4.7
EBITDA margin (%)	11.3	11.7	(2.9)	11.6	11.9	(2.8)	11.5	11.8	(2.8)
Adj. PBT	57.2	54.2	5.5	63.9	60.6	5.5	68.5	64.8	5.6
Adj. PAT	48.6	46.1	5.5	54.3	51.5	5.5	58.2	55.1	5.6
Adjusted EPS – Basic (cents)	17.4	16.5	5.5	18.8	17.8	5.5	20.2	19.1	5.6
Net debt/(cash)	51.2	52.7	(2.8)	11.5	14.5	(20.4)	(34.6)	(29.5)	17.5


Source: Zeus Research estimates

Exhibit 2: Revenue growth trend (pro forma, LTM)



Source: Company reports and Zeus Research estimates

Exhibit 3: Decrease in net debt (\$m)



Source: Company reports and Zeus Research estimates

Exhibit 4: Discounted cash flow valuation

\$m	2020	2021	2022E	2023E	2024E	2025E	2026E	2027E	2028E
<b>Turnover</b>	240.0	410.5	617.1	654.1	693.4	728.1	764.5	802.7	842.9
Growth (%)		71.0	50.3	6.0	6.0	5.0	5.0	5.0	5.0
EBITDA	29.4	46.3	70.0	75.7	79.7	87.4	95.6	104.4	109.6
Margin (%)	12.2	11.3	11.3	11.6	11.5	12.0	12.5	13.0	13.0
Net Capital Expenditure	(4.3)	(3.6)	(7.4)	(7.8)	(8.3)	(8.7)	(9.1)	(9.6)	(10.1)
Cap Ex % Revenue	1.8	0.9	1.2	1.2	1.2	1.2	1.2	1.2	1.2
Growth in CAPEX (%)		(16.5)	109.2	5.5	5.5	5.0	5.0	5.0	5.0
Working Capital	4.1	1.5	(1.7)	(6.8)	(1.0)	0.0	0.0	0.0	0.0
% Revenue	(1.7)	(0.4)	0.3	1.0	0.1	0.0	0.0	0.0	0.0
<b>Free Cash Flow</b>	<b>29.3</b>	<b>44.2</b>	<b>60.8</b>	<b>61.1</b>	<b>70.4</b>	<b>78.7</b>	<b>86.4</b>	<b>94.8</b>	<b>99.5</b>
Terminal Value	486.1								
Sum of discounted cash flows	349.4								
Total NPV of cashflows	835.5								
Net Debt/ (Cash)	65.0								
<b>Implied Equity value (\$m)</b>	<b>770.5</b>								
# diluted shares	295.5								
<b>Implied share price (p)</b>	<b>220.9</b>								
WACC (%)	11.7								
Growth in perpetuity (%)	2.0								

Source: Company reports and Zeus Research estimates

---

## Investment case

CentralNic is a market leader in two high growth markets – digital advertising and domain name management. The Online Marketing division grew 65% and the Online Presence division grew 9% in 2021. In addition to delivering strong growth, both divisions have attractive business models. They generate reliable revenues based on subscriptions and serve diversified customer bases. CentralNic's strong growth, high revenue visibility, operating leverage and high cash conversion are undervalued by its shares' low multiples. The shares trade at only 6x 2022 EBITDA, 8x P/E and 12.5% FCF yield. Our DCF valuation is 221p, well above the current share price.

### Large, high growth market

CentralNic's Online Marketing division grew revenue 65% pro forma in 2021. Privacy trends are accelerating demand for CentralNic's first-party, data-driven advertising solutions. Google updated the market in June 2021 that it will remove support for third-party cookies in its market leading Chrome browser by 2023. Apple already updated its iOS operating system in April 2021 with new privacy controls that limit digital advertisers' ability to track iPhone users across apps and websites owned by other companies (third party). Google recently announced that it may follow suit in the next two years. As a result of these changes, we believe brands are channelling advertising budgets towards advertising solutions that can unlock and refine consumer purchasing intent without third party cookies. CentralNic's Online Marketing division (particularly PubTONIC) can source, qualify and deliver high conversion traffic to advertisers without the use of any cookies. The global digital advertising market is expected to grow 8% CAGR from \$396bn in 2020 to \$502bn in 2024, representing a rise in share from 59% to 66% of the total advertising market, excluding US political advertising revenue.

CentralNic's Online Presence division grew 9% pro forma in 2021, driven by recovery from the impact of Covid and the company's investments in growth. The company has improved account management, resulting in increased revenues from top accounts. In addition, the division has strengthened its global infrastructure, which positions it strongly in a market dominated by local competitors. The company's investment programme has allowed the Online Presence division to grow faster than the market. The market is driven by the global ecommerce market, which is expected to grow 9% CAGR 2021-2024.

### Market leader times two

The Online Marketing division is a market leader in both high-conversion traffic generation and domain name parking. PubTONIC is growing faster than peers and taking market share with innovative new products. ParkingCrew is one of the largest and professional competitors in the domain name monetisation market, with estimated 27% market share based on our domains managed analysis.

In March, CentralNic announced the acquisition of VGL Verlagsgesellschaft mbH (VGL), Germany's largest provider of product comparison websites. VGL is a high growth company with a dominant market position. Revenue grew 30% CAGR 2018-21 to \$55m and EBITDA margin reached 20% in 2021. The acquisition offers opportunities to cross-sell traffic, reduce traffic acquisition costs and leverage VGL's content creation expertise. The company adds customers (e.g. Amazon) and traffic from c. 270m annual visitors, about double estimated visitors to which.co.uk.

The Online Presence division leads the domain names wholesaler market, with over 26m domains managed and c. 26k reseller customers. The Registry Solutions business within the wholesale business is ranked top five globally based on over 98 TLDs on its registry platform. Within the Registry Solutions business, CentralNic is the leading provider of Registry Solutions for nTLDs with 46% share, approximately equal to the next five competitors combined.

---

## Strong business model

### Reliable and diversified revenue base

The Online Marketing division operates attractive business models with reliable revenues and diversified customer bases. PubTONIC and ParkingCrew operate subscription revenue models and serves thousands of SMEs around the world.

The Online Presence division also has high revenue reliability. Domain names have high renewal rates. They are very sticky and have high switching costs and, particularly after the initial years. Companies are reluctant to switch domain names because search engines and traffic flows are highly dependent on domain names and email addresses are tied to domain names. As a result, renewal rates are typically about 80% in the second year and improve thereafter.

### Strong financial track record

CentralNic has upgraded revenue expectations six times and EBITDA four times since the beginning of 2021. CentralNic grew c. 37% organically in 2021 and we conservatively forecast 37% pro forma revenue growth in 2022.

Cash conversion should rise as acquisition related costs continue to reduce. FCFF/ Adjusted EBITDA ratio rose from 56% in 2020 to 75% in 2021. Improving FCF has driven net debt down from 2.9 times EBITDA at the beginning of 2021 to 0.9x at the end of H1 2022.

### Acquisition synergies

CentralNic plans to vertically integrate within the Online Marketing market. CentralNic plans to acquire web properties and publishing networks to provide organic traffic for its platform to monetise through digital advertising (PubTONIC). Acquisitions of existing partners enhances margins and secures revenues. CentralNic would then no longer need to pay for direct traffic, allowing it to keep more of the margin. In addition, vertical integration locks in a customer and increases market share where the acquired publishing network uses competing ad networks that CentralNic can substitute. Acquiring web properties also reduces CentralNic's reliance on other acquisition channels such as social media and display.

CentralNic's size, broad product suite and proven acquisition integration capabilities put the Online Presence division also in a strong position to consolidate the market. The domain name markets remain largely fragmented with competitors often owner managed. This should provide substantial opportunities for CentralNic to deliver synergies by consolidating technology platforms, reducing administration costs and increasing sales productivity. The company has already provided evidence of synergies from recent acquisitions. We see the Online Presence division further consolidating the market and delivering synergies for investors.

## Forecasts

### Exhibit 5: Income statement

Year to December (\$m)	2020A	2021A	2022E	2023E	2024E
Online Presence	127.9	149.3	155.7	160.4	165.2
Online Marketing	112.1	261.3	461.4	493.6	528.2
Turnover:	240.0	410.5	617.1	654.1	693.4
Online Presence	45.1	53.3	55.6	57.2	58.9
Online Marketing	30.0	65.2	115.2	123.3	131.9
Gross Profit	75.1	118.5	170.8	180.5	190.9
SG&A	(45.7)	(72.2)	(100.8)	(104.9)	(111.2)
Adj. EBITDA	29.4	46.3	70.0	75.7	79.7
Margin (%)	12.2	11.3	11.3	11.6	11.5
Margin based on Gross Profit (%)	39.1	39.0	41.0	41.9	41.8
Depreciation	(2.1)	(3.5)	(3.9)	(4.0)	(4.0)
Adj. EBIT	27.3	42.7	66.1	71.7	75.7
Adj Interest	(8.7)	(10.8)	(8.9)	(7.7)	(7.2)
Adjusted PBT	18.6	31.9	57.2	63.9	68.5
Tax	1.0	(5.1)	(8.6)	(9.6)	(10.3)
Adjusted PAT	19.6	26.8	48.6	54.3	58.2
<b>Reconciliation to reported numbers:</b>					
Adjusted PBT	18.6	31.9	57.2	63.9	68.5
Share based payments	(5.1)	(5.0)	(3.5)	(3.5)	(3.5)
Amortisation	(13.7)	(18.3)	(9.2)	(8.2)	(8.2)
Share of associate income/ FX	(2.2)	1.6	0.0	0.0	0.0
Exceptional finance costs/income	(1.1)	0.0			
Exceptional costs/income	(8.3)	(8.7)	(1.4)	(0.4)	(0.4)
Reported PBT	(11.9)	1.6	43.1	51.8	56.3
Tax	1.0	(5.1)	(7.3)	(8.8)	(9.6)
Reported PAT	(10.9)	(3.5)	35.8	43.0	46.7

Source: Company reports and Zeus estimates

## Exhibit 6: Balance sheet

Year to Dec (\$m)	2020A	2021A	2022E	2023E	2024E
PP&E	2.2	1.8	6.8	10.0	13.6
Intangible assets	262.2	261.0	320.3	313.7	306.2
Deferred receivables	0.7	0.4	0.4	0.4	0.4
Investments	0.1	0.1	0.1	0.1	0.1
Deferred tax assets	5.4	8.6	8.6	8.6	8.6
Non-current assets	270.6	271.8	336.1	332.7	328.8
Trade and other receivables	47.9	71.4	72.2	73.1	74.0
Inventories	1.0	0.9	0.9	0.9	0.9
Cash & cash equivalents	28.7	56.1	110.0	139.7	175.8
Current assets	77.6	128.4	183.2	213.7	250.7
Total Assets	348.2	400.2	519.2	546.4	579.5
<b>Liabilities</b>					
Trade and other payables	(89.3)	(117.0)	(116.2)	(110.3)	(110.2)
Taxation payable	-	-	(0.6)	(0.9)	(1.1)
Lease liabilities	(1.3)	(1.8)	(1.8)	(1.8)	(1.8)
Derivative financial instruments	-	(6.4)	(6.4)	(6.4)	(6.4)
Borrowings	(5.8)	(11.9)	(11.9)	(11.9)	(11.9)
Current liabilities	(96.4)	(137.1)	(136.8)	(131.3)	(131.4)
Other payables	(2.9)	(4.4)	(3.4)	(2.4)	(2.4)
Lease liabilities	(5.2)	(5.1)	(4.1)	(4.1)	(3.1)
Deferred tax liabilities	(22.0)	(20.3)	(20.3)	(20.3)	(20.3)
Derivative financial instruments	-	-	-	-	-
Borrowings	(107.8)	(119.3)	(143.0)	(133.0)	(123.0)
Long term liabilities	(137.9)	(149.1)	(170.8)	(159.8)	(148.8)
Total Liabilities	(234.3)	(286.2)	(307.7)	(291.1)	(280.2)
Net assets	113.9	114.0	211.6	255.3	299.3
<b>Equity</b>					
Share capital	0.3	0.3	0.3	0.3	0.3
Share premium	39.8	39.8	98.1	98.1	98.1
Merger relief reserve	5.3	5.3	5.3	5.3	5.3
Share based payments reserve	11.0	19.5	23.0	26.6	30.1
Cash flow hedging reserve	-	(6.4)	(6.4)	(6.4)	(6.4)
FX reserves	1.4	2.9	2.9	2.9	2.9
Retained earnings	56.1	52.5	88.3	128.5	168.9
Total Equity	113.9	114.0	211.6	255.3	299.3

Source: Company reports and Zeus estimates

## Exhibit 7: Cash flow statement

Year to December (\$m)	2020A	2021A	2022E	2023E	2024E
<b>Cash flow from operating activities</b>					
Profit /(Loss) before taxation	(11.8)	1.6	43.1	51.8	56.3
<b>Adjustments for:</b>					
Depreciation of property, plant and equipment	2.1	3.5	3.9	4.0	4.0
Amortisation of intangible assets	13.7	18.3	9.2	8.2	8.2
Share of associate income	(0.2)	-	-	-	-
Gain on sale of associate	(0.3)	-	-	-	-
Finance cost (net)	9.8	10.8	8.9	7.7	7.2
Share-based payments	5.1	5.0	3.5	3.5	3.5
Decrease in trade and other receivables	(8.1)	(18.8)	(0.9)	(0.9)	(0.9)
Increase in trade and other payables and accruals	12.2	20.0	(0.9)	(5.9)	(0.1)
Decrease in inventories	-	0.3	-	-	-
Cash flow from operations	22.7	40.7	66.9	68.5	78.3
Income tax paid	(2.0)	(2.2)	(6.8)	(8.4)	(9.4)
Net cash flow generated from operating activities	20.7	38.4	60.1	60.1	68.9
<b>Cash flow used in investing activities</b>					
Purchase of property, plant and equipment	(1.3)	(0.7)	(6.8)	(7.2)	(7.6)
Purchase of intangible assets, net of cash acquired	(3.0)	(2.8)	(0.7)	(0.7)	(0.7)
Payment of deferred consideration	(5.5)	(1.7)	(1.0)	(1.0)	-
Proceeds from disposal of investment in associate	1.8	-	-	-	-
Acquisition of subsidiaries, net of cash acquired	(37.1)	(18.3)	(69.9)	-	-
Net cash flow used in investing activities	(45.0)	(23.6)	(78.3)	(8.8)	(8.3)
<b>Cash flow used in financing activities</b>					
Proceeds from borrowings and repayments	2.2	26.6	23.7	(10.0)	(10.0)
Bond arrangement fees	(0.6)	(0.6)	-	-	-
Proceeds from issuance of ordinary shares (net)	34.7	-	58.3	-	-
Payment of finance leases	(1.1)	(2.0)	(1.0)	(1.0)	(1.0)
Dividends paid	-	-	-	(2.8)	(6.3)
Interest paid	(9.5)	(8.6)	(8.9)	(7.7)	(7.2)
Net cash flow generated from financing activities	25.6	15.4	72.1	(21.5)	(24.5)
Net increase in cash and cash equivalents	1.4	30.2	53.9	29.7	36.1
Cash and cash equivalents at beginning of the year	26.2	28.7	56.1	110.0	139.7
Exchange differences on cash and cash equivalents	1.1	(2.7)	-	-	-
Cash and cash equivalents at end of the year	28.7	56.1	110.0	139.7	175.8

Source: Company reports and Zeus estimates



# Disclaimer

This document is issued by Zeus Capital Limited ("Zeus") (Incorporated in England & Wales No. 4417845), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority ("FCA") for designated investment business, (Reg No. 224621) and is a member firm of the London Stock Exchange.

**Bob Liao, CFA is the author of this Investment Research. Bob Liao, CFA is an Investment Research Analyst and has been employed by Zeus to produce this research. There is no planned update to this research recommendation. The previous recommendation for CentralNic was Positive published 23/05/2022.**

Zeus is contractually engaged and paid by CentralNic to produce research on an ongoing basis and as such, this research constitutes a minor non-monetary benefit. This research is made available at the time that it is first published to all professional clients and eligible counterparties via numerous research aggregators.

Unless otherwise stated any share prices used in this document are taken after market close on the business day prior to the date of publication. The date of completion and first dissemination of this research recommendation are the same and are as per the date-time displayed at the top of the document, unless otherwise stated. If the document references views of analysts other than the author named above then please refer to the price chart or rating history table for the date/time of completion and first dissemination with respect to that view.

This document is issued by Zeus (Incorporated in England & Wales No. 4417845), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority ("FCA") for designated investment business, (Reg No. 224621) and is a member firm of the London Stock Exchange.

This document is for information purposes only and neither the information contained, nor the opinions expressed, within this document constitute or are to be construed as an offer or a solicitation of an offer to buy or sell the securities or other instruments mentioned in it. It or any part of it does not form the basis of and should not be relied upon in connection with any contract. Subject to the nature and contents of the document, the investments described herein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal the amount invested. Certain investments contained in the document may have tax implications for private customers whereby levels and basis of taxation may be subject to change. Zeus does not provide tax advice and investors should seek advice from a tax adviser.

Zeus uses reasonable efforts to obtain information from sources which it believes to be reliable but the contents of this document have been prepared without any substantive analysis being undertaken into the companies concerned or their securities and it has not been independently verified. No representation or warranty, either express or implied, is made nor responsibility of any kind is accepted by Zeus, its directors or employees either as to the accuracy or completeness of any information stated in this document.

Opinions expressed are the current opinions of Zeus as of the date appearing on this material only. The information and opinions are provided for the benefit of Zeus clients as at the date of this document and are subject to change without notice. Opinions and information disclosed in this publication may have been disclosed to the issuer prior to publication and subsequently amended. There is no regular update series for research issued by Zeus.

The document is not to be construed as a solicitation or recommendation of investment advice and no personal recommendation is being made to you; the securities referred to may not be suitable for you and should not be relied upon in substitution for the exercise of independent judgement. You should make your own investment decisions based upon your own financial objectives and financial resources. Neither past performance nor forecasts are a reliable indication of future performance and Investors may realise losses on any investments, including possible loss of the principal amount invested. Products are not insured by any government or government agencies and are neither

guaranteed, insured, nor a deposit account or other obligation of any depository institution.

Zeus and any company or person connected with it (including its officers, directors and employees) may have a position or holding in any investment mentioned in this document or a related investment, and such positions or holdings may be inconsistent with this research recommendation, and may from time to time dispose of any such securities or instrument. In the last 12 months Zeus may have been a manager, or co-lead manager, in the underwriting or placement of securities to the issuers of securities mentioned in this document within the last 12 months, or may have had corporate finance mandates or may have received compensation for investment banking services from such companies. Zeus, Capital Limited may be, or may have been, party to an agreement with the issuer of the securities mentioned in this document relating to the production of this recommendation. Zeus may receive or may intend to seek compensation for investment banking services from such companies within the next 3 months. A senior executive or director of Zeus or a connected person may be an officer, director or adviser of any issuer of securities mentioned in this document. Accordingly, recipients of this document should not rely on this document being impartial and information may be known to Zeus or persons connected with it which is not reflected in its material.

Zeus has in place a number of mechanisms for identifying and managing potential conflicts which include: Policies and procedures to identify, consider, manage and monitor potential conflicts of interests. Internal guidance and training regarding the identification of possible conflicts before they arise. Procedures to ensure that potential conflicts are escalated to the appropriate level within Zeus.

Internal arrangements (including physical separation and other information barriers) for regulating the flow of information between and within business areas.

Zeus shall not be liable for any direct or indirect damages, including lost profits arising in any way from the information contained in this material. This material is for the use of intended recipients only and only for distribution to professional and institutional investors, i.e. persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 of the United Kingdom, or persons who have been categorised as professional customers or eligible counterparties under the rules of FCA. It is not intended for retail customers.

This document is being supplied to you solely for your information and may not be reproduced, re-distributed or passed to any other person or published in whole or in part for any purpose. This material is not directed at you if Zeus is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to you and persons into whose possession this material comes should inform themselves about, and observe any such restrictions.

## Important Disclosures for United States Persons

Zeus may distribute research, in reliance on Rule 15a-6(a)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), directly to persons in the United States ("U.S.") that are "major US institutional investors" as defined pursuant to Rule 15a-6(b)(4) (each an "MII"). With respect to any distribution of this report to a U.S. person, the information contained in this report (i) is intended solely for use by MII, (ii) was prepared by the analyst named on the cover of this report, who is a non-U.S. research analyst and, as such, may not be subject to all requirements applicable to U.S.-based analysts, (iii) is not subject to all of the independence and disclosure standards applicable to research reports prepared for retail investors, and (iv) may not be used or relied upon by anyone that is not a MII for any purpose. Any U.S. person receiving this report represents and agrees, by virtue of its acceptance thereof, that it is a MII and that it understands the risks involved in executing transactions in such securities.

Any MII that is the recipient of this research and wishes to discuss or receive additional information regarding any security or issuer mentioned herein, or

engage in any transaction to purchase or sell or solicit or offer the purchase or sale of such securities, should contact a registered representative of Beech Hill Securities, Inc. (a U.S. broker-dealer registered with the Securities and Exchange Commission and a Member of the Financial Industry Regulatory Authority, Inc.) via telephone at +1 (212) 350-7200 or at its offices at 880 Third Avenue, 16th Floor, New York, NY 10022. Any transaction by such persons (other than a registered U.S. broker-dealer or bank acting in a broker-dealer capacity) must be effected with or through Beech Hill Securities, Inc.

Neither the report nor any analyst who prepared or approved the report is subject to the full scope of U.S. legal or regulatory requirements pertaining to research reports or research analysts. Zeus is neither registered as a broker-dealer under the Exchange Act nor a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization. To the extent this report relates to non-U.S. securities, note that investing in non-U.S. securities may entail particular risks. Such securities may not be registered under the U.S. Securities Act of 1933, as amended, and the issuer of such securities may not be subject to U.S. reporting and/or other requirements. Financial statements included in a research report with respect to such securities, if any, may have been prepared in accordance with non-U.S. accounting standards that may not be comparable to the financial statements of U.S. companies. Available information regarding the issuers of such securities may be limited, and such issuers may not be subject to the same auditing and reporting standards as U.S. issuers. Fluctuations in the values of national currencies, as well as the potential for governmental restrictions on currency movements, can significantly erode principal and investment returns. Market rules, conventions and practices may differ from U.S. markets, adding to transaction costs or causing delays in the purchase or sale of such securities. Securities of some non-U.S. companies may not be as liquid as securities of comparable U.S. companies.

The information contained herein may include forward-looking statements within the meaning of U.S. federal securities laws that are subject to risks and uncertainties. Factors that could cause a company's actual results and financial condition to differ from expectations include, without limitation: political uncertainty, changes in general economic conditions that adversely affect the level of demand for the company's products or services, changes in foreign exchange markets, changes in international and domestic financial markets and in the competitive environment, and other factors relating to the foregoing. All forward-looking statements contained in this report are qualified in their entirety by this cautionary statement.

Neither Beech Hill Securities, Inc. nor any affiliate thereof accepts any liability whatsoever for any direct or consequential loss of any kind arising out of the use or reliance on the information given. Research does not take into account the specific investment objectives and financial situation of any recipient, nor does it provide individually tailored investment advice or offer tax, regulatory, accounting or legal advice. Prior to entering into any proposed transaction, recipients should determine, in consultation with their own investment, legal, tax, regulatory and accounting advisors, the economic risks and merits, as well as the legal, tax, regulatory and accounting characteristics and consequences, of any transaction. Investors seeking to buy or sell any financial instruments discussed or recommended in any research report should seek independent financial advice relating thereto.

The products discussed in this report are not FDIC insured, may lose value and are not guaranteed by any Beech Hill Securities, Inc. or Zeus party.

### Analyst Certification

Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report.

### Additional Disclosures


This material was produced by Zeus solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. This document does not constitute an offer of, or an invitation by or on behalf of Zeus or its affiliates or any other company to any

person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which Zeus or its

Affiliates consider to be reliable. Zeus does not accept any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. By accepting this document you agree that you have read the above disclaimers, acknowledge them and agree to be bound by all of the foregoing limitations, restrictions and provisions.

1. Zeus or its Affiliates have not recently been the beneficial owners of 1% or more of the securities mentioned in this report.
2. Zeus or its Affiliates have not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
3. Zeus or its Affiliates have received compensation for investment banking services from the issuer of these securities in the past 12 months.
4. However, one or more person of Zeus, or its affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon either on their own account or on behalf of their clients.
5. As of the publication of this report Zeus, does not make a market in the subject securities.
6. Zeus, or its Affiliates may, to the extent permitted by law, act upon or use the above material or the conclusions stated above or the research or analysis on which they are based before the material is published to recipients and from time to time provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

### 12 Month Recommendation History



Recommendation distribution at 30 June 2022 Source: Zeus

### 12 Month Recommendation History

Nomad & Broker	11
Nomad & Joint Broker	12
Joint Broker	6
Financial Adviser & Broker	1
Research client	8

At 30 June 2022 Source: Zeus

---

Zeus is a leading independent financial services group working across public and private capital markets in the UK. Our core services include Investment Banking, Equity Sales, Research and Trading, and Investment Management.

We are a highly entrepreneurial firm with a strong track record working with ambitious founders, innovators and their teams to realise the potential of their businesses.

---

**London** 10 Old Burlington Street London, W1S 3AG  
Tel: +44 20 3829 5000

---

**Manchester** 82 King Street Manchester, M2 4WQ  
Tel: +44 161 831 1512

---

**Birmingham** 3 Brindleyplace Birmingham, B1 2JB  
Tel: +44 121 231 7210

---

**Edinburgh** 58 North Castle Street Edinburgh, EH2 3LU  
Tel: +44 131 370 3704

---

[info@zeuscapital.co.uk](mailto:info@zeuscapital.co.uk)  
<https://zeuscapital.co.uk>

ZEUS